HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwartz, G.N. Articles by Perdue, J.F. Search for Related Content PubMed PubMed Citation Articles by Schwartz, G.N. Articles by Perdue, J.F.

Comparative Effects of Insulin-Like Growth Factor II (IGF-II) and IGF-II Mutants Specific for IGF-II/CIM6-P or IGF-I Receptors on in Vitro Hematopoiesis

^a Transplantation Therapy Section, National Cancer Institute, Bethesda, Maryland, USA;
^b Otsuka America Pharmaceutical Company, Rockville, Maryland, USA;
^c Daiichi Pharmaceutical Company, LTD, Molecular Biology Research Laboratory, Tokyo, Japan;
^d Immune Cell Biology Program, Naval Medical Research Institute, Bethesda, Maryland, USA;
^e Holland Laboratories, Molecular Biology Laboratory, American Red Cross, Rockville, Maryland, USA

Key Words. Colony-forming units for granulocytes-macrophages (CFU-GM) • Burst-forming units-erythroid (BFU-E) • Insulin-like growth factor II (IGF-II) • Megakaryocyte • Interleukin 3 • c-kit ligand

Correspondence: Dr. Gretchen N. Schwartz, Bldg. 10, Rm. 12N226, Transplantation Therapy Section, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

This report presents the results of studies investigating the effect of insulin-like growth factor II (IGF-II) on the proliferation and differentiation of CD34⁺ bone marrow cells in serum-substituted liquid cultures. Bone marrow cells were enriched for CD34⁺ cells and then placed in liquid cultures supplemented with either interleukin 3 (IL-3) or IL-3 and c-kit ligand with and without the addition of IGF-II. When CD34⁺ cells were incubated with IL-3, cellularity increased throughout four weeks of culture. Cellularity was twofold greater when cultures also contained IGF-II. IGF-II also promoted an increase in cellularity in cultures with IL-3 and c-kit ligand. In combination with IL-3 or IL-3 and c-kit ligand, IGF-II promoted an earlier differentiation of granulocytes, as well as an increase in the number of megakaryocyte lineage cells. There were approximately two-fold more colony-forming units for granulocytes and macrophages (CFU-GM) and burst-forming units for erythroid cells (BFU-E) in cultures containing both IL-3 and IGF-II than in cultures with IL-3 alone. These results demonstrate that in cytokine-supplemented media, physiological concentrations of IGF-II augmented both the proliferation and differentiation of CD34⁺ bone marrow cells while maintaining a greater number of progenitor cells. To identify the receptors through which IGF-II enhances in vitro hematopoiesis, IGF-II was substituted with one of the mutant forms of IGF-II that selectively interacts with either IGF-II/CIM6-P receptors or with IGF-I and insulin receptors. The results with the mutant forms of IGF-II demonstrate that IGF-II augments in vitro hematopoiesis primarily through its interaction with IGF-I and possibly insulin receptors, rather than IGF-II/CIM6-P receptors.

This article has been cited by other articles:

				R. S. Douglas, A. G. Gianoukakis, S. Kamat, and T. J. Smith Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves' Disease May Carry Functional Consequences for Disease Pathogenesis J. Immunol., March 1, 2007; 178(5): 3281 - 3287. [Abstract] [Full Text] [PDF]

				D. Pink, D. Schoeler, T. Lindner, P. C. Thuss-Patience, A. Kretzschmar, H. Knipp, U. Vanhoefer, and P. Reichardt Severe Hypoglycemia Caused by Paraneoplastic Production of IGF-II in Patients With Advanced Gastrointestinal Stromal Tumors: A Report of Two Cases J. Clin. Oncol., September 20, 2005; 23(27): 6809 - 6811. [Full Text] [PDF]

				P. Ioannidis, L. G. Mahaira, S. A. Perez, A. D. Gritzapis, P. A. Sotiropoulou, G. J. Kavalakis, A. I. Antsaklis, C. N. Baxevanis, and M. Papamichail CRD-BP/IMP1 Expression Characterizes Cord Blood CD34+ Stem Cells and Affects c-myc and IGF-II Expression in MCF-7 Cancer Cells J. Biol. Chem., May 20, 2005; 280(20): 20086 - 20093. [Abstract] [Full Text] [PDF]

				C. C. Zhang and H. F. Lodish Insulin-like growth factor 2 expressed in a novel fetal liver cell population is a growth factor for hematopoietic stem cells Blood, April 1, 2004; 103(7): 2513 - 2521. [Abstract] [Full Text] [PDF]

				L. Duplomb, B. Chaigne-Delalande, P. Vusio, S. Raher, Y. Jacques, A. Godard, and F. Blanchard Soluble Mannose 6-Phosphate/Insulin-Like Growth Factor II (IGF-II) Receptor Inhibits Interleukin-6-Type Cytokine-Dependent Proliferation by Neutralization of IGF-II Endocrinology, December 1, 2003; 144(12): 5381 - 5389. [Abstract] [Full Text] [PDF]

				G. N. Schwartz, U. Kammula, M. K. Warren, M. K. Park, X.-Y. Yan, F. M. Marincola, and R. E. Gress Thrombopoietin and Chemokine mRNA Expression in Patient Post-Chemotherapy and In Vitro Cytokine-Treated Marrow Stromal Cell Layers Stem Cells, September 1, 2000; 18(5): 331 - 342. [Abstract] [Full Text]

				W. Zumkeller and S. Burdach The Insulin-Like Growth Factor System in Normal and Malignant Hematopoietic Cells Blood, December 1, 1999; 94(11): 3653 - 3657. [Full Text] [PDF]